@HKennecke @SyedAAhmad5 @ASCO @SWOG @rachnatshroff @CathyEngMD @sepideh_gholami The short answer is we don’t know. The 💡 behind #NAT is to deliver DD. We started giving 6 mo in borderline resectable #PDAC but there is data to give Tx until CA19-9 normaliz
We have data that suggests FFX>GA as adjuvant therapy. APACT (link below) GA=gem and PRODIGE FFX>gem. Thus, adjuvant FFX>GA, assuming eligible for FFX. @ASCO_pubs @EileenMOReilly @cancerassassin1 @SyedAAhmad5 @mkatzmd @SocSurgOnc https://t.co/K7rt
@SyedAAhmad5 @DavendraSohal @ShaalanBeg @CathyEngMD @SWOG @rachnatshroff @agrothey @mkatzmd @HKennecke @GIcancerDoc @DenboJw @LeeOcuin @Shrikhande_SV @MarcBesselink We had similar pCR with pre-op gem/tax (for 6mo) in borderline disease. There is no data to
Recent pubs re: outcomes & potential advantages 2 neoadjuvant therapy in pancreatic cancer: http://t.co/0c8bGNUMPb & http://t.co/hzZUvTzpwe
Recent pubs re: outcomes & potential advantages 2 neoadjuvant therapy in pancreatic cancer: http://t.co/0c8bGNUMPb & http://t.co/hzZUvTzpwe
Extended #neoadjuvant therapy extends #PancreaticCancer survival from Dr. Vince Picozzi @PanCAN MAB Chair http://t.co/GYZRvzfY4O